Treatment Outcomes: Switching from Idursulfase to Idursulfase Beta (Hunter Syndrome)
Source: Dr. Anna Kulpanovich et al. (2025). National Medical Centre "Mother and Child", Belarus.

Study Design

Retrospective Case Series

Population

N = 7 Patients (Switch due to shortage)

Comparison

Elaprase (Pre) vs Hunterase (Post)

Patient
Elaprase Phase
Hunterase Phase
Range
Deceased (†)

Key Results

  • GAG Levels: Continued significant decrease after switch.
  • Functional Capacity (6MWT): Performance remained stable or improved (>500m).
  • Organomegaly: Liver and Spleen size showed ongoing reduction post-switch.

Safety & Conclusions

  • Safety Profile: No new adverse events or specific safety concerns identified.
  • Conclusion: Switching to Idursulfase Beta maintained or extended therapeutic benefits without introducing new risks.